The aim of this study was to assess the mediatory effect of SNPs in the circadian clock on metabolic syndrome. Patients (n=517) recruited from 80 health care districts in Finland first underwent a comprehensive health examination wherein their blood was analyzed for blood glucose, cholesterol, triglycerides, gamma-glutamyltransferase and uric acid concentrations. This was followed up with a diagnostic mental health interview with patients’ mental health and seasonality assessed via the Composite International Diagnostic Interview and the Seasonal Pattern Assessment Questionnaire. The US Adult Treatment Panel III of the National Cholesterol Education Program (NCEP-ATPIII) criteria and the International Diabetes Federations (IDF) criteria were used to determine metabolic syndrome status.
After adjusting for multiple comparisons, the npas2 SNP rs11541353 was found to be associated with high blood pressure, with the minor allele having a protective effect. These results were consistent even when the sample size included individuals taking hypertension medication. The per2 10870 SNP was found to be associated with fasting blood glucose, with the minor allele reducing the risk of increased plasma glucose levels.
rs11541353 in npas2